Hexarelin should not be described as acting only on growth-hormone measurements. Human experiments have investigated other endocrine responses, but the results also require attention to timing and study design.
An acute dose-response study measured GH, prolactin and cortisol changes. A separate longer-exposure study did not find the same simple pattern of progressive pituitary-adrenal or prolactin overstimulation under its regimen. These observations are not interchangeable, and neither supports a universal prediction for an individual.
A transient response is not a diagnosis
A short-lived laboratory change does not by itself establish a chronic endocrine disorder. Conversely, lack of a particular persistent change in a small study is not proof that every use is safe.
This prevents two common overstatements: “it raises a hormone, so it inevitably causes disease,” and “one longer study looked reassuring, so the concern can be ignored.” Both discard the conditions under which the observations were made.
Symptoms also cannot automatically be attributed to a single result. Breast symptoms, mood changes or other concerns require assessment of the person and the complete exposure history; a forum cannot establish the mechanism from a description alone.
The practical question for a clinician is which findings are clinically relevant and what investigation is appropriate. It is not how to add another research compound to counteract a suspected hormone effect.
The sources here were reviewed at abstract level. Their different measurement windows are enough to show why a simplistic claim is unreliable, but full methods and later evidence are needed before stronger clinical conclusions.
A careful summary can acknowledge that hexarelin has broader endocrine effects without overstating their consequences. That balanced description is more useful than either a selective-action marketing claim or a guaranteed-harm narrative. It also provides no evidence that a specific research vial matches the studied intervention.